Changes in patterns of retention in HIV care and antiretroviral treatment in Tanzania between 2008 and 2016: an analysis of routinely collected national programme data.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
Jun 2019
Historique:
entrez: 18 4 2019
pubmed: 18 4 2019
medline: 7 5 2019
Statut: ppublish

Résumé

Tanzania is a high HIV burden country in Sub-Saharan Africa with 1.5 million people infected. Unless monitored and responded to, low levels of retention in care may lead to poor HIV associated clinical outcomes and an increased likelihood of onward viral transmission. Using routine data, we assessed changes in retention in care and on treatment for HIV over time in Tanzanian facilities, using the national care and treatment programme (CTC) database. Data were extracted from the CTC database and analysed using two approaches: a series of cross-sectional analyses for each calendar year between 2008 and 2016 to assess the changing characteristics of the population in care and on treatment, and, a longitudinal analysis using survival analysis methods for a series of cohorts representing i) all engaging in care and ii) all initiating treatment in each calendar year from 2008 to 2015. Multivariate analyses were carried out to explore the independent effect of calendar year when controlling for other factors. The total number of individuals enrolled in care increased from 160 268 in 2008 to 548 296 in 2016. The percentage of the in-care population enrolled for more than 3 years increased from 9.9% in 2008 to 54.5% in 2016. The overall rates of retention in care were 80.9%, 57.3% and 45.4% at 12, 24 and 36 months respectively. The rates of retention on antiretroviral therapy (ART) ART at 12, 24 and 36 months after treatment-initiation were 83.9%, 64.0% and 53.5%. There were small but statistically significant differences in the retention rates between cohorts and evidence for a significant decrease in the rates of retention in the most recent years analysed. Data from Tanzania show that while the number of People Living with HIV (PLHIV) who were in care and monitored through the routine data system increased over time, the retention rates in care and treatment remained relatively stable. These rates were similar to other regional estimates. Systematic reviews of tracing studies indicate that mortality among those lost to follow up has decreased over time, partly underpinned by an increase in the numbers transferring between clinics. True retention rates may therefore be higher than we report here, and this underpins the need for data systems that can track patients between clinics.

Sections du résumé

BACKGROUND BACKGROUND
Tanzania is a high HIV burden country in Sub-Saharan Africa with 1.5 million people infected. Unless monitored and responded to, low levels of retention in care may lead to poor HIV associated clinical outcomes and an increased likelihood of onward viral transmission. Using routine data, we assessed changes in retention in care and on treatment for HIV over time in Tanzanian facilities, using the national care and treatment programme (CTC) database.
METHODS METHODS
Data were extracted from the CTC database and analysed using two approaches: a series of cross-sectional analyses for each calendar year between 2008 and 2016 to assess the changing characteristics of the population in care and on treatment, and, a longitudinal analysis using survival analysis methods for a series of cohorts representing i) all engaging in care and ii) all initiating treatment in each calendar year from 2008 to 2015. Multivariate analyses were carried out to explore the independent effect of calendar year when controlling for other factors.
RESULTS RESULTS
The total number of individuals enrolled in care increased from 160 268 in 2008 to 548 296 in 2016. The percentage of the in-care population enrolled for more than 3 years increased from 9.9% in 2008 to 54.5% in 2016. The overall rates of retention in care were 80.9%, 57.3% and 45.4% at 12, 24 and 36 months respectively. The rates of retention on antiretroviral therapy (ART) ART at 12, 24 and 36 months after treatment-initiation were 83.9%, 64.0% and 53.5%. There were small but statistically significant differences in the retention rates between cohorts and evidence for a significant decrease in the rates of retention in the most recent years analysed.
CONCLUSIONS CONCLUSIONS
Data from Tanzania show that while the number of People Living with HIV (PLHIV) who were in care and monitored through the routine data system increased over time, the retention rates in care and treatment remained relatively stable. These rates were similar to other regional estimates. Systematic reviews of tracing studies indicate that mortality among those lost to follow up has decreased over time, partly underpinned by an increase in the numbers transferring between clinics. True retention rates may therefore be higher than we report here, and this underpins the need for data systems that can track patients between clinics.

Identifiants

pubmed: 30992984
doi: 10.7189/jogh.09.010424
pii: jogh-09-010424
pmc: PMC6445500
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

010424

Déclaration de conflit d'intérêts

Conflict of interest: The authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no conflict of interest.

Références

PLoS Med. 2011 Jul;8(7):e1001056
pubmed: 21811403
Afr J AIDS Res. 2011 Dec;10(4):393-401
pubmed: 25865373
Curr Opin HIV AIDS. 2016 Jan;11(1):102-8
pubmed: 26545266
J Int AIDS Soc. 2012 Nov 19;15(2):17383
pubmed: 23199799
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Bull World Health Organ. 2008 Jul;86(7):559-67
pubmed: 18670668
BMC Public Health. 2015 May 22;15:501
pubmed: 25994129
J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e44-51
pubmed: 26375466
PLoS One. 2017 Oct 12;12(10):e0186316
pubmed: 29023510
J Epidemiol Community Health. 2006 Oct;60(10):846-50
pubmed: 16973529
MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):945-52
pubmed: 24280913
Glob Health Action. 2012 Nov 09;5:1-9
pubmed: 23151364
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S228-32
pubmed: 23764640
Clin Infect Dis. 2016 Mar 1;62(5):648-654
pubmed: 26567263
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
Health Econ Policy Law. 2009 Apr;4(Pt 2):179-93
pubmed: 19187569
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
Trop Med Int Health. 2012 Dec;17(12):1509-20
pubmed: 22994151
Trop Med Int Health. 2012 Apr;17(4):497-506
pubmed: 22296265

Auteurs

Paul Mee (P)

The MeSH Consortium, London School of Hygiene and Tropical Medicine, London, UK.
Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK.

Brian Rice (B)

The MeSH Consortium, London School of Hygiene and Tropical Medicine, London, UK.
Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Liis Lemsalu (L)

The MeSH Consortium, London School of Hygiene and Tropical Medicine, London, UK.
Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Department of Drug and Infectious Diseases Epidemiology, National Institute for Health Development, Tallinn, Estonia.

James Hargreaves (J)

The MeSH Consortium, London School of Hygiene and Tropical Medicine, London, UK.
Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Veryeh Sambu (V)

Strategic Information Unit, National AIDS Control Programme, Dodoma Tanzania.

Richelle Harklerode (R)

University of California San Francisco, Global Health Sciences, San Francisco, California, USA.

Jim Todd (J)

The MeSH Consortium, London School of Hygiene and Tropical Medicine, London, UK.
Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK.

Geoffrey Somi (G)

Strategic Information Unit, National AIDS Control Programme, Dodoma Tanzania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH